Phenotype of obesity and gastroesophageal reflux disease in the context of comorbidity in patients with cardiovascular diseases


Cite item

Full Text

Abstract

The relevance of studying such problems as gastroesophageal reflux disease (GERD) and obesity is caused by their high prevalence in the developed countries of the world. Epidemiological data indicate that obesity is a significant risk factor for developing GERD due to increased intra-abdominal pressure and gastroesophageal gradient, slowing of gastric evacuation and formation of hiatal hernia. Abdominal obesity increases the likelihood of complications of GERD: erosive esophagitis, Barrett's esophagus and adenocarcinoma. This fact is connected with humoral influences: increased production of pro-inflammatory cytokines and leptin, and decreased secretion of adiponectin. Treatment of comorbid patients requires higher dosages and longer courses of antisecretory medicines, and an additional prescription of ursodeoxycholic acid.

About the authors

I V Maev

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

д.м.н., проф., академик РАН, зав. каф. пропедевтики внутренних болезней и гастроэнтерологии Moscow, Russia

G L Yurenev

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: yurenev@list.ru
д.м.н., проф. каф. пропедевтики внутренних болезней и гастроэнтерологии Moscow, Russia

E M Mironova

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

клинический аспирант каф. пропедевтики внутренних болезней и гастроэнтерологии Moscow, Russia

T V Yureneva-Thorzhevskaya

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

к.м.н., с.н.с. лаб. пульмонологии НИМСИ Moscow, Russia

References

  1. Dent J. An evidence - based appraisal of reflux disease management - the Genval Workshop report. Gut. 1999;(44):1-16. doi: 10.1136/gut.44.2008.s1
  2. Di Mario F, Goni E. Gastric acid secretion: changes during a century. Best Pract Res Clin Gastroenterol. 2014;28(6):953-65. doi: 10.1016/j.bpg.2014.10.006
  3. Vakil N, van Zanten S.V, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease (GERD) - a global evidence - based consensus. Am J Gastroenterol. 2006;(101):1900-20. doi: 10.1093/pch/14.suppl.a.26a
  4. Locke G.R, Talley N.J, Weaver A.L, Zinsmeister A.R. A new questionare for gastroesophageal reflux disease. Mayo Clin Proe. 1994;69:539-47. doi: 10.1016/s0025-6196(12)62245-9
  5. Юренев Г.Л., Самсонов А.А., Юренева-Тхоржевская Т.В. Современный взгляд на кардиальные проявления гастроэзофагеальной рефлюксной болезни. Сonsilium Medicum. 2015;17(12):44-9.
  6. Маев И.В., Бурков С.Г., Юренев Г.Л. Гастроэзофагеальная рефлюксная болезнь и ассоциированная патология. М.: Литтерра, 2014. 352 с.
  7. Маев И.В., Трухманов А.С. Неэрозивная рефлюксная болезнь с позиций современной гастроэнтерологии: клинические особенности и влияние на качество жизни пациентов. Русский медицинский журнал. 2004;12(23):1344-8.
  8. Tytgat G.N. Recent developments in gastroesophageal reflux disease and Barrett's esophagus: ANNO 2012. J Dig Dis. 2012;13(6):291-5. doi: 10.1111/j.1751-2980.2012.00598.x
  9. Rubenstein J.H, Shaheen N.J. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology. 2015;149(2):302-17. doi: 10.1053/j.gastro.2015.04.053
  10. Castro A.V, Kolka C.M, Kim S.P, Bergman R.N. Obesity, insulin resistance and comorbidities? Mechanisms of association. Arq Bras Endocrinol Metabol. 2014;58(6):600-9.
  11. Haidar Y.M, Cosman B.C. Obesity epidemiology. Clin Colon Rectal Surg. 2011;24(4):205-10. doi: 10.3390/ijerph110707425
  12. Дедов И.И., Мельниченко Г.А., редакторы. Ожирение: этиология, патогенез, клинические аспекты: Руководство для врачей. М.: Медицинское информационное агентство, 2004.
  13. Mehta T, Fontaine K.R, Keith S.W, Bangalore S.S, de los Campos G, Bartolucci A, Pajewski N.M, Allison D.B. Obesity and mortality: are the risks declining? Evidence from multiple prospective studies in the United States. Obes Rev. 2014;15(8):619-29. doi: 10.1111/obr.12191
  14. Gray D.S. Diagnosis and prevalence of obesity. Med Clin North Am. 1989;73(1):1-13.
  15. Ze E.Y, Kim B.J, Kang H, Kim J.G. Abdominal visceral to subcutaneous adipose tissue ratio is associated with increased risk of erosive esophagitis. Dig Dis Sci. 2017;62(5):1265-71. doi: 10.1007/s10620-017-4467-4
  16. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. 1956. Nutrition. 1999;15(1):89-90. discussion 1.
  17. Peppa M, Koliaki C, Papaefstathiou A, Garoflos E, Katsilambros N, Raptis S.A, Hadjidakis D.I, Dimitriadis G.D. Body composition determinants of metabolic phenotypes of obesity in nonobese and obese postmenopausal women. Obesity (Silver Spring). 2013;21(9):1807-14. doi: 10.1002/oby.20227
  18. Slawik M, Vidal-Puig A.J. Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev. 2006;5(2):144-64. doi: 10.1016/j.arr.2006.03.004
  19. Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013;7(1):14-24. doi: 10.1007/s11684-013-0262-6
  20. Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014;43(1):161-73. doi: 10.1016/j.gtc.2013.11.009
  21. Ogunwobi O, Mutungi G, Beales I.L. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology. 2006;147(9):4505-16. doi: 10.1210/en.2006-0224
  22. Rubenstein J.H, Kao J.Y, Madanick R.D, Zhang M, Wang M, Spacek M.B, Donovan J.L, Bright S.D, Shaheen N.J. Association of adiponectin multimers with Barrett's oesophagus. Gut. 2009;58(12):1583-9. doi: 10.1136/gut.2008.171553
  23. Kelesidis I, Kelesidis T, Mantzoros C.S. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94(9):1221-5. doi: 10.1038/sj.bjc.6603051
  24. Исаченкова О.А. Пищевое поведение как важный фактор развития ожирения и коморбидных с ним заболеваний. Ожирение и метаболизм. 2015;12(4):14-7
  25. Wadden T.A, Phelan S. Assessment of quality of life in obese individuals. Obes Res. 2002 Nov;10 Suppl 1:50-7. doi: 10.1038/oby.2002.190
  26. Yanagisawa M, Yu R.K. The expression and functions of glycoconjugates in neural stem cells. Glycobiology. 2007 Jul;17(7):57-74. doi: 10.1093/glycob/cwm018
  27. Vaishnav B, Bamanikar A, Maske P, Reddy A, Dasgupta S. Gastroesophageal reflux disease and its association with body mass index: clinical and endoscopic study. J Clin Diagn Res. 2017;11(4):01-04. doi: 10.7860/JCDR/2017/24151.9562
  28. Suter M, Dorta G, Giusti V, Calmes J.M. Gastro - esophageal reflux and esophageal motility disorders in morbidly obese patients. Obes Surg. 2004;14(7):959-66. doi: 10.1381/0960892041719581
  29. Quiroga E, Cuenca-Abente F, Flum D. Impaired esophageal function in morbidly obese patients with gastroesophageal reflux disease: evaluation with multichannel intraluminal impedance. Surg Endosc. 2006;20(5):739-43. doi: 10.1007/s00464-005-0268-5
  30. Трухманов А.С., Евсютина Ю.В. Изжога при гастроэзофагеальной рефлюксной болезни - механизм развития и подходы к терапии. Русский медицинский журнал. 2017;(10):707-10.
  31. Трухманов А.С., Джахая Н.Л., Кайбышева В.О., Сторонова О.А. Новые аспекты рекомендаций по лечению больных гастроэзофагеальной рефлюксной болезнью. Гастроэнтерология и гепатология. 2013;1(4):1-9.
  32. Kouklakis G, Moschos J, Kountouras J, Mpoumponaris A, Molyvas E, Minopoulos G. Relationship between obesity and gastroesophageal reflux disease as recorded by 3-hour esophageal pH monitoring. Rom J Gastroenterol. 2005;14(2):117-21.
  33. Koppman J.S, Poggi L, Szomstein S, Ukleja A, Botoman A, Rosenthal R. Esophageal motility disorders in the morbidly obese population. Surg Endosc. 2007 May;21(5):761-4. doi: 10.1007/s00464-006-9102-y
  34. Kahrilas P.J, Shi G, Manka M, Joehl R.J. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology. 2000;118(4):688-95.
  35. Fisher B.L, Pennathur A, Mutnick J.L, Little A.G. Obesity correlates with gastroesophageal reflux. Dig Dis Sci. 1999;44(11):2290-4. doi: 10.1023/A:1026617106755
  36. Маев И.В., Юренев Г.Л., Бурков С.Г. Многоликая ГЭРБ: проблемы и решения. М.: ГЭОТАР-Медиа; 2015; 386 с.
  37. Wu J.C, Mui L.M, Cheung C.M, Chan Y, Sung J.J. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology. 2007;132(3):883-9. doi: 10.1053/j.gastro.2006.12.032
  38. Bredenoord A.J. Mechanisms of reflux perception in gastroesophageal reflux disease: a review. Am J Gastroenterol. 2012;107(1):8-15. doi: 10.1038/ajg.2011.286
  39. Pandolfino J.E, El-Serag H.B, Zhang Q, Shah N, Ghosh S.K, Kahrilas P.J. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130(3):639-49. doi: 10.1053/j.gastro.2005.12.016
  40. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003;290(1):66-72. doi: 10.1001/jama.290.1.66
  41. El-Serag H.B, Graham D.Y, Satia J.A, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005;100(6):1243-50. doi: 10.1111/j.1572-0241.2005.41703.x
  42. Jacobson B.C, Somers S.C., Fuchs C.S, Kelly C.P, Camargo C.A. Jr. Body - mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006 Jun 1;354(22):2340-8.
  43. Nocon M, Labenz J, Willich S.N. Lifestyle factors and symptoms of gastro - oesophageal reflux - a population - based study. Aliment Pharmacol Ther. 2006;23(1):169-74. doi: 10.1111/j.1365-2036.2006.02727.x
  44. Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, Locke G.R 3rd, Rodriguez-Artalejo F. Symptoms of gastro - oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther. 2004;19(1):95-105.
  45. Kang M.S, Park D.I, Oh S.Y, Yim H.J, Chun H.J, Lee H.S. Abdominal obesity is an independent risk factor for erosive esophagitis in a Korean population. J Gastroenterol Hepatol. 2007;22(10):1656-61. doi: 10.1111/j.1440-1746.2006.04518.x
  46. Ma X.Q, Cao Y, Wang R, Yan X, Zhao Y, Zou D, Wallander M-A, Johansson S, Liu W, Gu Z, Zhao J, He J. Prevalence of, and factors associated with, gastroesophageal reflux disease: a population - based study in Shanghai, China. Dis Esophagus. 2009;22(4):317-22. doi: 10.1111/j.1442-2050.2008.00904.x
  47. Lagergren J, Bergstrom R, Nyren O. No relation between body mass and gastro - oesophageal reflux symptoms in a Swedish population based study. Gut. 2000;47(1):26-9.
  48. Lee H.L, Eun C.S, Lee O.Y. Association between GERD-related erosive esophagitis and obesity. J Clin Gastroenterol. 2008;42(6):672-5. doi: 10.1097/MCG.0b013e31806daf64
  49. Hampel H, Abraham N.S, El-Serag H.B. Meta - analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199-211.
  50. El-Serag H.B, Hashmi A, Garcia J, Richardson P, Alsarraj A, Fitzgerald S, Vela M, Shaib Y, Abraham N.S, Velez M, Cole R, Rodriguez M.B, Anand B, Graham D.Y, Kramer J.R. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: a case - control study. Gut. 2013. doi: 10.1136/gutjnl-2012-304189
  51. Rubenstein J.H, Morgenstern H, Chey W.D. Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett’s oesophagus. Gut. 2013. doi: 10.1136/gutjnl-2012-304103
  52. Smith K.J, O'Brien S.M, Smithers B.M, Gotley D.C, Webb P.M, Green A.C, Whiteman D.C. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14(11 Pt 1):2481-6. doi: 10.1158/1055-9965.EPI-05-0370
  53. Pohl H, Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142-6. doi: 10.1093/jnci/dji024
  54. Chow W.H, Blot W.J, Vaughan T.L, Risch H.A, Gammon M.D, Stanford J.L, Dubrow R, Schoenberg J.B, Mayne S.T, Farrow D.C, Ahsan H, West A.B, Rotterdam H, Niwa S, Fraume J.F. Jr. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90(2):150-5.
  55. Hoyo C, Cook M.B, Kamangar F, Freedman N.D, Whiteman D.C, Bernstein L, Brown L.M, Risch H.A, Ye W, Sharp L, Wu A.H, Ward M.H, Casson A.G, Murray L.J, Corley D.A, Nyrén O, Pandeya N, Vaughan T.L, Chow W.H, Gammon M.D. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012;41(6):1706-18. doi: 10.1093/ije/dys176
  56. Weigle D.S. Leptin and other secretory products of adipocytes modulate multiple physiological functions. Ann Endocrinol (Paris). 1997;58(2):132-6.
  57. Rubenstein J.H, Dahlkemper A, Kao J.Y, Zhang M, Morgenstern H, Mc Mahon L, Inadomi J.M. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol. 2008;103(6):1358-64. doi: 10.1111/j.1572-0241.2008.01823.x
  58. Ливзан М.А., Лаптева И.В., Кролевец Т.С., Киселев И.Е. Специфические особенности ГЭРБ, связанной с ожирением и избыточной массой тела. Терапевтический архив. 2016;88(2):21-7.
  59. Anand G, Katz P.O. Gastroesophageal reflux disease and obesity. Gastroenterol Clin North Am. 2010 Mar;39(1):39-46. doi: 10.1016/j.gtc.2009.12.002
  60. Kotlyar M, Carson S.W. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther. 1999;37(1):8-19.
  61. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39:215-31.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies